New revelations in CRISPR patent battle

Jon Cohen, Science Magazine, 5 October 2016,

Two new developments in the CRISPR patent battle may alter who gains control of the lucrative technology.  The Broad Institute has asked patent officials to separate four patents from the current dispute with UC Berkeley, which would allow them to be judged in separate proceedings.  This may ultimately allow both UC Berkeley and the Broad Institute to gain control of CRISPR intellectual property.  Additionally, the pharmaceutical company Cellectis is claiming an umbrella patent covering “most of the gene editing procedures done with a nuclease” including CRISPR/Cas9, zinc fingers, and TALENs.  Other parties are disputing Cellectis’s claims.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply